Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …

This is the seventh special EBMT report on the indications for haematopoietic stem cell
transplantation for haematological diseases, solid tumours and immune disorders. Our aim …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

The first classification on this topic categorized cardiomyopathies as heart muscle diseases
with dilated (DCM), hypertrophic, restrictive, arrhythmogenic right ventricular (ARVC), or …

Tissue deposition of protein fibrils causes a group of rare diseases called systemic
amyloidoses. This Seminar focuses on changes in their epidemiology, the current approach …

Importance Many patients with systemic amyloidosis are underdiagnosed. Overall, 25% of
patients with immunoglobulin light chain (AL) amyloidosis die within 6 months of diagnosis …

PURPOSE Oral melphalan and dexamethasone (MDex) were considered a standard of care
in light-chain (AL) amyloidosis. In the past decade, bortezomib has been increasingly used …

The amyloidoses are a group of systemic diseases characterized by organ deposition of
misfolded protein fragments of diverse origins. The natural history of the disease …

Purpose Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and
the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N …

This is the sixth special report that the European Society for Blood and Marrow
Transplantation regularly publishes on the current practice and indications for …